Cosmo Bio Co

Cosmo Bio Co Change in Working Capital

The Change in Working Capital of Cosmo Bio Co (3386.T) as of Nov 5, 2026 is 18.00 M JPY. In the previous year, Change in Working Capital was -139.00 M JPY — a change of -112.95% (higher).

Change in Working Capital

18.00 MJPY

YoY

-112.95%

Last updated:

Change in Working Capital of Cosmo Bio Co is 2025 18.00 M JPY. Change in Working Capital of Cosmo Bio Co was 2024 -139.00 M JPY. It decreases by -112.95% higher compared to the previous year.

The Cosmo Bio Co Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
393.00 M JPY
Jan 1, 2019
2.00 M JPY
Jan 1, 2020
-31.00 M JPY
Jan 1, 2021
-217.00 M JPY
Jan 1, 2022
-367.00 M JPY
Jan 1, 2023
162.00 M JPY
Jan 1, 2024
-139.00 M JPY
Jan 1, 2025
18.00 M JPY
The Cosmo Bio Co Change in Working Capital history
YEARChange in Working CapitalYoY
18.00 MJPY-112.95%
-139.00 MJPY-185.80%
162.00 MJPY-144.14%
-367.00 MJPY+69.12%
-217.00 MJPY+600.00%
-31.00 MJPY-1,650.00%
2.00 MJPY-99.49%
393.00 MJPY-444.74%
-114.00 MJPY-618.18%
22.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Change in Working Capital of Cosmo Bio Co is 18.00 M JPY in 2025.

Change in Working Capital of Cosmo Bio Co changed from -139.00 M JPY to 18.00 M JPY, representing a -112.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co